Även om Cell Impacts utveckling går långsammare än vi tidigare prognostiserat bedömer vi att affärsi...
Redeye provides a preview of Northbaze's Q3 results, set to be released on November 21.
Redeye provides a research update following the Q3 report published by Cinclus earlier today.
Net sales and EBIT were in line with our estimates.
We lift '24e EBITDA by 27%, '25-'26e up 9-4% Doro now closer to a done deal, could lift '28e EBITA ~...
Zoomability Int AB (”Zoomability” eller ”Bolaget”) har under åren 2023 och 2024 fortsatt stärka Bola...
Redeye provides its initial take on Navigo’s Q3 2024 report, which came in considerably below our es...
Xplora Technologies AS has made a move to acquire Doro AB, offering a 38% premium to shareholders.
Redeye is again positively surprised to see CTEK beating our estimates on the top line and profitabi...
Redeye comments on Fable Media Group’s Q3 results, which came in somewhat lower than expected in ter...
Redeye returns with an update following Alzecure's Q3 report.
Signs SEK 132m expansion order from Swedish Space Corporation New run-rate of ~SEK 250m is 37% above...
Redeye comments on Thunderful Group’s Q3’24 report, which was weaker than expected, primarily due to...
Redeye comments on Embracer’s Q2-results which were somewhat weaker than expected, owing mainly to P...
Redeye updates its view on Lifecare following its Q3 report.
Redeye is encouraged by the new management in Sivers, guiding for a long-term ambition of reaching a...
Redeye comments on Better Collective’s Q3-results which were in line with the preliminary announceme...
Redeye updates on Gentoo Media following Q3-results where we have made limited changes to estimates ...
Solid outlook remains for an acceleration in Q4 Limited sales and adj.
Redeye provides an update on Scandinavian ChemoTech following the Q3 2024 report.